The short answer
Trials use a combination rule usually called Hy's Law: transaminases above three times the upper limit of normal, total bilirubin above twice the upper limit, without an alternative explanation such as biliary obstruction. Enzyme elevation alone does not meet it.
Key facts
- Named after
- Hyman Zimmerman
- Component 1
- ALT or AST above 3× upper limit of normal
- Component 2
- Total bilirubin above 2× upper limit
- Component 3
- No alternative cause; ALP not markedly raised
- Significance
- Predicts risk of severe outcome
- Enzyme rise alone
- Common, usually not meaningful
Why one measurement is not enough
Transaminases leak from damaged liver cells, so a rise indicates injury to hepatocytes. But mild rises are extremely common, occur with many drugs and with none, and usually resolve without consequence. A threshold on enzymes alone would flag enormous numbers of clinically irrelevant events.
What bilirubin adds
Function rather than damage. Bilirubin is cleared by the liver, so a rise means the organ's capacity to do its job has been compromised, not merely that some cells were injured. Damage plus loss of function is a more serious combination than damage alone, and requiring both is what makes the rule discriminating.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the exclusion matters
Bilirubin also rises when bile cannot drain (a gallstone, a stricture, a tumour). That is obstruction rather than drug toxicity. Checking that alkaline phosphatase is not disproportionately elevated distinguishes hepatocellular injury from a blocked biliary tree, and without that step the rule would capture the wrong patients.
Why the combination is taken so seriously
Zimmerman's observation was that patients meeting these criteria had a substantial risk of progressing to liver failure or death. That empirical association is what gives the rule its weight. It is a pattern that predicted severe outcomes, not an arbitrary regulatory threshold.
The detection problem this creates
Idiosyncratic drug-induced liver injury is rare, often around one in several thousand exposures or rarer. A Phase 2b trial of a few hundred participants is simply too small to observe such an event reliably, so a clean liver result at that stage is reassuring but not conclusive. This is why the danuglipron case (one participant) was treated as significant despite being a single observation.
How to read a safety statement
No cases of drug-induced liver injury is a specific claim about this rule being met by nobody. Liver enzyme elevations were in line with approved agents is a quite different and much weaker statement. Both appeared in the recent oral GLP-1 literature, attached to different compounds, and the difference between them is the whole story.
Quick reference
| Finding | What it means | Weight |
|---|---|---|
| ALT/AST raised only | Hepatocyte damage | Common, often unimportant |
| Bilirubin raised too | Function impaired | Serious in combination |
| ALP also high | Suggests obstruction | Points away from drug injury |
Frequently asked questions
What is Hy's Law?
Transaminases above 3× the upper limit of normal, total bilirubin above 2×, with no alternative explanation such as biliary obstruction.
Why does bilirubin matter so much?
It reflects impaired function rather than mere cell damage. Damage plus loss of function predicts severe outcomes; damage alone usually does not.
Can a Phase 2b trial rule out liver injury?
No. Idiosyncratic injury may occur in one in several thousand exposures, which a few hundred participants cannot exclude.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Obesity Drug That Is Not an IncretinSetmelanotide targets the melanocortin-4 receptor, not GLP-1. An approved medicine for rare genetic obesity, and a different mechanism entirely.
- The Survodutide Comparison, Read ProperlyAn open-label semaglutide arm in a type 2 diabetes dose-finding trial. Why that is weaker evidence than a head-to-head, and what the numbers mean.
- Failing to Show Non-Inferiority Is Not Showing InferiorityREDEFINE 4 missed its non-inferiority endpoint. That is a specific statistical statement, and it is not the same as the drug being worse.
- Satiety and Nausea Run Through Different CircuitsA 2024 Nature paper showed hindbrain GLP-1 receptor circuits for satiety and aversion are dissociable. Nausea may not be the price of appetite suppression.
- Three Head-to-Heads, One Common ComparatorSURMOUNT-5, REDEFINE 4 and TRIUMPH-5 all use tirzepatide. What it means when one compound becomes the field's reference point.